Brokerages Set Krystal Biotech, Inc. (NASDAQ:KRYS) Price Target at $206.67

Krystal Biotech, Inc. (NASDAQ:KRYS) has been given an average rating of “Buy” by the eight analysts that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation, six have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $206.67.

KRYS has been the subject of a number of recent analyst reports. Chardan Capital reissued a “buy” rating and issued a $212.00 target price on shares of Krystal Biotech in a research note on Wednesday, December 18th. Citigroup increased their price target on shares of Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Stifel Nicolaus upped their target price on shares of Krystal Biotech from $204.00 to $220.00 and gave the company a “buy” rating in a research note on Wednesday, September 11th. Finally, HC Wainwright reissued a “buy” rating and set a $221.00 price target on shares of Krystal Biotech in a research report on Wednesday, December 18th.

Insider Transactions at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the completion of the transaction, the insider now directly owns 1,475,882 shares of the company’s stock, valued at $243,195,835.96. This represents a 1.67 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 14.10% of the stock is owned by insiders.

Institutional Investors Weigh In On Krystal Biotech

Several institutional investors have recently bought and sold shares of the company. Segall Bryant & Hamill LLC raised its holdings in shares of Krystal Biotech by 352.4% in the third quarter. Segall Bryant & Hamill LLC now owns 157,144 shares of the company’s stock valued at $28,605,000 after purchasing an additional 122,407 shares during the last quarter. State Street Corp increased its stake in Krystal Biotech by 9.0% in the 3rd quarter. State Street Corp now owns 1,452,811 shares of the company’s stock valued at $264,455,000 after buying an additional 119,936 shares during the last quarter. Principal Financial Group Inc. lifted its position in Krystal Biotech by 1,972.0% during the 2nd quarter. Principal Financial Group Inc. now owns 123,469 shares of the company’s stock worth $22,674,000 after buying an additional 117,510 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Krystal Biotech by 115.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 193,767 shares of the company’s stock valued at $35,583,000 after acquiring an additional 103,928 shares in the last quarter. Finally, Franklin Resources Inc. increased its position in shares of Krystal Biotech by 34.2% in the third quarter. Franklin Resources Inc. now owns 243,760 shares of the company’s stock valued at $43,774,000 after acquiring an additional 62,178 shares during the last quarter. Institutional investors own 86.29% of the company’s stock.

Krystal Biotech Price Performance

Shares of NASDAQ:KRYS opened at $158.33 on Wednesday. The stock has a market cap of $4.55 billion, a price-to-earnings ratio of 89.45 and a beta of 0.85. The company has a 50 day moving average of $176.51 and a 200-day moving average of $184.05. Krystal Biotech has a one year low of $107.50 and a one year high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last released its earnings results on Monday, November 4th. The company reported $0.91 EPS for the quarter, topping analysts’ consensus estimates of $0.84 by $0.07. The firm had revenue of $83.84 million during the quarter, compared to analyst estimates of $82.94 million. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The business’s quarterly revenue was up 879.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.67) EPS. Equities research analysts anticipate that Krystal Biotech will post 2.97 earnings per share for the current year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).